Skip to content

A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00509873
Enrollment
578
Registered
2007-08-01
Start date
2007-08-31
Completion date
2008-06-30
Last updated
2011-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial Conjunctivitis

Brief summary

The study will determine the safety and efficacy of gatifloxacin eye drops in patients with bacterial conjunctivitis

Interventions

Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily

Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily

Sponsors

Allergan
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
1 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Clinically diagnosed with bacterial conjunctivitis

Exclusion criteria

* Signs and/or symptoms of conjunctivitis for more than 96 hours * Signs and/or symptoms suggestive of fungal, viral, or allergic conjunctivitis * Clinical diagnosis of chlamydia in either eye

Design outcomes

Primary

MeasureTime frameDescription
Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6Day 6Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye at Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe).

Secondary

MeasureTime frameDescription
Percentage of Patients With Clinical Improvement of Ocular Signs at Day 6Day 6Percentage of patients with clinical improvement of ocular signs at Day 6 based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe), defined as a decrease (improvement) from Day 1 (Baseline) in the total score of conjunctival hyperemia and mucopurulent discharge (pus),with no increase (worsening) from Day 1 (Baseline) in either individual variable in the study eye.
Percentage of Patients With Microbiological Cure at Day 6Day 6Percentage of patients with microbiological cure, defined such that all bacteria present in the study eye at Day 1 (Baseline) are eradicated (or absent) at Day 6 based on a Classification of Microbial Response. (Eradication=pathogen is absent in follow-up culture; Reduction=pathogen is reduced from baseline below threshold count in follow-up culture; Persistence=pathogen reduced from baseline but is above or equal to threshold count in follow-up culture; and Proliferation=pathogen has increased in count from baseline in follow-up culture)
Percentage of Patients With Clinical Improvement of Ocular Symptoms at Day 6Day 6Percentage of patients with clinical improvement of ocular symptoms at Day 6, defined as a decrease (improvement) from Day 1 (Baseline) in the total score of itching and tearing (each on 4-point scale: 0 = none, 1 = mild, 2 = moderate, and 3 = severe), with no increase (worsening) from Day 1 (Baseline) in any individual score in the study eye diagnosed with bacterial conjunctivitis

Countries

United States

Participant flow

Participants by arm

ArmCount
Gatifloxacin 0.5% Eye Drops
Gatifloxacin 0.5% eye drops
287
Placebo Eye Drops
Placebo eye drops
291
Total578

Baseline characteristics

CharacteristicGatifloxacin 0.5% Eye DropsPlacebo Eye DropsTotal
Age, Customized
1-18 years
123 participants123 participants246 participants
Age, Customized
19-65 years
126 participants141 participants267 participants
Age, Customized
>65 years
38 participants27 participants65 participants
Sex: Female, Male
Female
161 Participants172 Participants333 Participants
Sex: Female, Male
Male
126 Participants119 Participants245 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
14 / 28813 / 289
serious
Total, serious adverse events
0 / 2881 / 289

Outcome results

Primary

Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6

Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye at Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe).

Time frame: Day 6

Population: Modified Intent to Treat; defined as all randomized patients who were culture positive at baseline meaning the culture of the eye grew bacteria. (Note: The Day 6 analysis included all Day 6 visit data, regardless of whether it was collected on Day 6 or on a later day).

ArmMeasureValue (NUMBER)
Gatifloxacin 0.5% Eye DropsPercentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 674.9 Percentage of Patients
Placebo Eye DropsPercentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 665.2 Percentage of Patients
Secondary

Percentage of Patients With Clinical Improvement of Ocular Signs at Day 6

Percentage of patients with clinical improvement of ocular signs at Day 6 based on a 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe), defined as a decrease (improvement) from Day 1 (Baseline) in the total score of conjunctival hyperemia and mucopurulent discharge (pus),with no increase (worsening) from Day 1 (Baseline) in either individual variable in the study eye.

Time frame: Day 6

Population: Modified Intent to Treat; defined as all randomized patients who were culture positive at baseline meaning the culture of the eye grew bacteria. (Note: The Day 6 analysis included all Day 6 visit data, regardless of whether it was collected on Day 6 or on a later day).

ArmMeasureValue (NUMBER)
Gatifloxacin 0.5% Eye DropsPercentage of Patients With Clinical Improvement of Ocular Signs at Day 697.0 Percentage of Patients
Placebo Eye DropsPercentage of Patients With Clinical Improvement of Ocular Signs at Day 696.2 Percentage of Patients
Secondary

Percentage of Patients With Clinical Improvement of Ocular Symptoms at Day 6

Percentage of patients with clinical improvement of ocular symptoms at Day 6, defined as a decrease (improvement) from Day 1 (Baseline) in the total score of itching and tearing (each on 4-point scale: 0 = none, 1 = mild, 2 = moderate, and 3 = severe), with no increase (worsening) from Day 1 (Baseline) in any individual score in the study eye diagnosed with bacterial conjunctivitis

Time frame: Day 6

Population: Modified Intent to Treat; defined as all randomized patients who were culture positive at baseline meaning the culture of the eye grew bacteria. (Note: The Day 6 analysis included all Day 6 visit data, regardless of whether it was collected on Day 6 or on a later day).

ArmMeasureValue (NUMBER)
Gatifloxacin 0.5% Eye DropsPercentage of Patients With Clinical Improvement of Ocular Symptoms at Day 685.5 Percentage of Patients
Placebo Eye DropsPercentage of Patients With Clinical Improvement of Ocular Symptoms at Day 682.2 Percentage of Patients
Secondary

Percentage of Patients With Microbiological Cure at Day 6

Percentage of patients with microbiological cure, defined such that all bacteria present in the study eye at Day 1 (Baseline) are eradicated (or absent) at Day 6 based on a Classification of Microbial Response. (Eradication=pathogen is absent in follow-up culture; Reduction=pathogen is reduced from baseline below threshold count in follow-up culture; Persistence=pathogen reduced from baseline but is above or equal to threshold count in follow-up culture; and Proliferation=pathogen has increased in count from baseline in follow-up culture)

Time frame: Day 6

Population: Modified Intent to Treat; defined as all randomized patients who were culture positive at baseline meaning the culture of the eye grew bacteria. (Note: The Day 6 analysis included all Day 6 visit data, regardless of whether it was collected on Day 6 or on a later day).

ArmMeasureValue (NUMBER)
Gatifloxacin 0.5% Eye DropsPercentage of Patients With Microbiological Cure at Day 689.2 Percentage of Patients
Placebo Eye DropsPercentage of Patients With Microbiological Cure at Day 661.4 Percentage of Patients
Post Hoc

Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge Up to Day 6

Percentage of patients that achieved clinical success, defined as achievement of a score of zero for both conjunctival hyperemia and conjunctival discharge in the study eye up to Day 6. Conjunctival hyperemia and conjunctival discharge were each assessed on a 4-point severity grade scale (0=none, +1=mild, +2=moderate, +3=severe). (Note: The Up to Day 6 analysis included all data up to the Day 6 time point but excluded any Day 6 visit data that was collected after the Day 6 time point).

Time frame: 6 Days

Population: Modified Intent to Treat; defined as all randomized patients who were culture positive at baseline meaning the culture of the eye grew bacteria. (Note: The Up to Day 6 analysis included all data up to the Day 6 time point but excluded any Day 6 visit data that was collected after the Day 6 time point).

ArmMeasureValue (NUMBER)
Gatifloxacin 0.5% Eye DropsPercentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge Up to Day 664.1 Percentage of Patients
Placebo Eye DropsPercentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge Up to Day 650.0 Percentage of Patients

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026